Stocks · News reference

ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

Oct 19, 2026, 3:52 PMVandana Singh

New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 21, 2026, 6:03 PM
ImmunityBio Announces Database Lock for Registrational Trial of ANKTIVA® Plus BCG
ImmunityBio has completed the database lock for Cohort A of its QUILT-2.005 registrational trial, which evaluates ANKTIVA in combination with BCG for BCG-naïve non-muscle invasive bladder cancer.
IBRX
BenzingaOct 21, 2026, 11:38 AMBenzinga Newsdesk
ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
IBRX
BenzingaOct 21, 2026, 11:37 AMBenzinga Newsdesk
ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
IBRX